132 related articles for article (PubMed ID: 20413845)
1. Expression profile of tyrosine phosphatases in HER2 breast cancer cells and tumors.
Lucci MA; Orlandi R; Triulzi T; Tagliabue E; Balsari A; Villa-Moruzzi E
Cell Oncol; 2010; 32(5-6):361-72. PubMed ID: 20413845
[TBL] [Abstract][Full Text] [Related]
2. Identification of protein tyrosine phosphatases and dual-specificity phosphatases in mammalian spermatozoa and their role in sperm motility and protein tyrosine phosphorylation.
González-Fernández L; Ortega-Ferrusola C; Macias-Garcia B; Salido GM; Peña FJ; Tapia JA
Biol Reprod; 2009 Jun; 80(6):1239-52. PubMed ID: 19211810
[TBL] [Abstract][Full Text] [Related]
3. Tyrosine phosphatases in the HER2-directed motility of ovarian cancer cells: Involvement of PTPN12, ERK5 and FAK.
Villa-Moruzzi E
Anal Cell Pathol (Amst); 2011; 34(3):101-12. PubMed ID: 21483099
[TBL] [Abstract][Full Text] [Related]
4. Transforming growth factor {beta} (TGF-{beta})-Smad target gene protein tyrosine phosphatase receptor type kappa is required for TGF-{beta} function.
Wang SE; Wu FY; Shin I; Qu S; Arteaga CL
Mol Cell Biol; 2005 Jun; 25(11):4703-15. PubMed ID: 15899872
[TBL] [Abstract][Full Text] [Related]
5. Integrative genome wide analysis of protein tyrosine phosphatases identifies CDC25C as prognostic and predictive marker for chemoresistance in breast cancer.
Topno R; Nazam N; Kumari P; Kumar M; Agarwal P
Cancer Biomark; 2021; 32(4):491-504. PubMed ID: 34275890
[TBL] [Abstract][Full Text] [Related]
6. Expression of HER-2 in MCF-7 breast cancer cells modulates anti-apoptotic proteins Survivin and Bcl-2 via the extracellular signal-related kinase (ERK) and phosphoinositide-3 kinase (PI3K) signalling pathways.
Siddiqa A; Long LM; Li L; Marciniak RA; Kazhdan I
BMC Cancer; 2008 May; 8():129. PubMed ID: 18454859
[TBL] [Abstract][Full Text] [Related]
7. Aberrant expression of novel and previously described cell membrane markers in human breast cancer cell lines and tumors.
Huang H; Groth J; Sossey-Alaoui K; Hawthorn L; Beall S; Geradts J
Clin Cancer Res; 2005 Jun; 11(12):4357-64. PubMed ID: 15958618
[TBL] [Abstract][Full Text] [Related]
8. The positive is inside the negative: HER2-negative tumors can express the HER2 intracellular domain and present a HER2-positive phenotype.
Panis C; Pizzatti L; Corrêa S; Binato R; Lemos GF; da Silva do Amaral Herrera AC; Seixas TF; Cecchini R; Abdelhay E
Cancer Lett; 2015 Feb; 357(1):186-195. PubMed ID: 25434795
[TBL] [Abstract][Full Text] [Related]
9. The nonreceptor-type tyrosine phosphatase PTPN13 is a tumor suppressor gene in non-small cell lung cancer.
Scrima M; De Marco C; De Vita F; Fabiani F; Franco R; Pirozzi G; Rocco G; Malanga D; Viglietto G
Am J Pathol; 2012 Mar; 180(3):1202-1214. PubMed ID: 22245727
[TBL] [Abstract][Full Text] [Related]
10. Transfection of human ovarian cancer cells with the HER-2/neu receptor tyrosine kinase induces a selective increase in PTP-H1, PTP-1B, PTP-alpha expression.
Wiener JR; Kassim SK; Yu Y; Mills GB; Bast RC
Gynecol Oncol; 1996 May; 61(2):233-40. PubMed ID: 8626139
[TBL] [Abstract][Full Text] [Related]
11. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM
J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962
[TBL] [Abstract][Full Text] [Related]
12. Suppression of cell migration is promoted by miR-944 through targeting of SIAH1 and PTP4A1 in breast cancer cells.
Flores-Pérez A; Marchat LA; Rodríguez-Cuevas S; Bautista VP; Fuentes-Mera L; Romero-Zamora D; Maciel-Dominguez A; de la Cruz OH; Fonseca-Sánchez M; Ruíz-García E; la Vega HA; López-Camarillo C
BMC Cancer; 2016 Jul; 16():379. PubMed ID: 27377268
[TBL] [Abstract][Full Text] [Related]
13. Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells.
Wang X; Wong J; Sevinsky CJ; Kokabee L; Khan F; Sun Y; Conklin DS
Mol Cancer Ther; 2016 Sep; 15(9):2198-208. PubMed ID: 27256378
[TBL] [Abstract][Full Text] [Related]
14. Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer cells.
Asanuma H; Torigoe T; Kamiguchi K; Hirohashi Y; Ohmura T; Hirata K; Sato M; Sato N
Cancer Res; 2005 Dec; 65(23):11018-25. PubMed ID: 16322251
[TBL] [Abstract][Full Text] [Related]
15. Differential gene expression patterns in HER2/neu-positive and -negative breast cancer cell lines and tissues.
Wilson KS; Roberts H; Leek R; Harris AL; Geradts J
Am J Pathol; 2002 Oct; 161(4):1171-85. PubMed ID: 12368191
[TBL] [Abstract][Full Text] [Related]
16. Protein kinase Calpha determines HER2 fate in breast carcinoma cells with HER2 protein overexpression without gene amplification.
Magnifico A; Albano L; Campaner S; Campiglio M; Pilotti S; Ménard S; Tagliabue E
Cancer Res; 2007 Jun; 67(11):5308-17. PubMed ID: 17545611
[TBL] [Abstract][Full Text] [Related]
17. Human epidermal growth factor receptor 2 regulates angiopoietin-2 expression in breast cancer via AKT and mitogen-activated protein kinase pathways.
Niu G; Carter WB
Cancer Res; 2007 Feb; 67(4):1487-93. PubMed ID: 17308086
[TBL] [Abstract][Full Text] [Related]
18. A pathway-based approach for identifying biomarkers of tumor progression to trastuzumab-resistant breast cancer.
Nam S; Chang HR; Jung HR; Gim Y; Kim NY; Grailhe R; Seo HR; Park HS; Balch C; Lee J; Park I; Jung SY; Jeong KC; Powis G; Liang H; Lee ES; Ro J; Kim YH
Cancer Lett; 2015 Jan; 356(2 Pt B):880-90. PubMed ID: 25449779
[TBL] [Abstract][Full Text] [Related]
19. NRF1 motif sequence-enriched genes involved in ER/PR -ve HER2 +ve breast cancer signaling pathways.
Ramos J; Das J; Felty Q; Yoo C; Poppiti R; Murrell D; Foster PJ; Roy D
Breast Cancer Res Treat; 2018 Nov; 172(2):469-485. PubMed ID: 30128822
[TBL] [Abstract][Full Text] [Related]
20. A class of genes in the HER2 regulon that is poised for transcription in breast cancer cell lines and expressed in human breast tumors.
Rahmatpanah FB; Jia Z; Chen X; Char JE; Men B; Franke AC; Jones FE; McClelland M; Mercola D
Oncotarget; 2015 Jan; 6(2):1286-301. PubMed ID: 25428913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
